Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
Conclusion.Combining cediranib with docetaxel + prednisone failed to demonstrate superior efficacy, compared with docetaxel + prednisone, and added toxicity. Our data do not support pursuing the combination further in patients with mCRPC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Elisabeth Heath, Lance Heilbrun, Heather Mannuel, Glenn Liu, Primo Lara, J. Paul Monk, Thomas Flaig, Amado Zurita, Philip Mack, Ulka Vaishampayan, Philip Stella, Daryn Smith, Susan Bolton, Arif Hussain, Anas Al-Janadi, Daniel Silbiger, Muhammad Usman, S. Tags: Prostate, Chinese Edition, Clinical Trial Results Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Clinical Trials | Docetaxel | Oral Cancer | Prednisone | Prostate Cancer | Taxotere | Toxicology